Advertisement
Canada markets close in 40 minutes
  • S&P/TSX

    22,153.51
    -193.25 (-0.86%)
     
  • S&P 500

    5,264.55
    -42.46 (-0.80%)
     
  • DOW

    39,088.59
    -582.45 (-1.47%)
     
  • CAD/USD

    0.7281
    -0.0025 (-0.34%)
     
  • CRUDE OIL

    76.83
    -0.74 (-0.95%)
     
  • Bitcoin CAD

    92,504.25
    -3,006.72 (-3.15%)
     
  • CMC Crypto 200

    1,460.54
    -42.12 (-2.80%)
     
  • GOLD FUTURES

    2,335.80
    -57.10 (-2.39%)
     
  • RUSSELL 2000

    2,042.82
    -38.89 (-1.87%)
     
  • 10-Yr Bond

    4.4750
    +0.0410 (+0.92%)
     
  • NASDAQ

    16,707.43
    -94.11 (-0.56%)
     
  • VOLATILITY

    13.24
    +0.95 (+7.73%)
     
  • FTSE

    8,339.23
    -31.10 (-0.37%)
     
  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     
  • CAD/EUR

    0.6732
    -0.0013 (-0.19%)
     

A Struggling Pfizer Looks for Help From a Wall Streeter

A Struggling Pfizer Looks for Help From a Wall Streeter

As the big drugmaker tries to turn its fortunes around by focusing on oncology, it has turned to a Citi analyst who hasn’t recommended the stock in over a decade. But Andrew Baum has something Pfizer needs: oncology expertise.